| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 20.49 | -3.07 | 3.04 | -3.72 |
Op profit growth | 23.05 | 30.09 | -24.8 | 27.38 |
EBIT growth | 21.41 | 17.45 | -40.14 | 50.01 |
Net profit growth | 637.66 | -94.49 | 65.22 | 268.35 |
Profitability ratios (%) | ||||
OPM | 19.14 | 18.74 | 13.96 | 19.13 |
EBIT margin | 14.47 | 14.36 | 11.85 | 20.4 |
Net profit margin | 8.09 | 1.32 | 23.26 | 14.5 |
RoCE | 9.54 | 7.42 | 5.4 | 8.66 |
RoNW | 2.53 | 0.36 | 6.33 | 3.69 |
RoA | 1.33 | 0.17 | 2.65 | 1.54 |
Per share ratios (₹) | ||||
EPS | 28.74 | 3.42 | 76.47 | 49.87 |
Dividend per share | 2.5 | 14 | 2 | 4.5 |
Cash EPS | 6.93 | -15.33 | 56.58 | 30.59 |
Book value per share | 309.61 | 282.18 | 275.26 | 307.39 |
Valuation ratios | ||||
P/E | 12.87 | 41.32 | 3.72 | 9.32 |
P/CEPS | 53.39 | -9.21 | 5.03 | 15.2 |
P/B | 1.19 | 0.5 | 1.03 | 1.51 |
EV/EBIDTA | 14.19 | 8.58 | 16.77 | 19.14 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 2.71 | 10.06 |
Tax payout | -9.59 | -4.72 | -6.93 | -16.72 |
Liquidity ratios | ||||
Debtor days | 112.4 | 120.28 | 120.71 | 134.37 |
Inventory days | 109.15 | 88.5 | 82.58 | 89.14 |
Creditor days | -134.8 | -125.48 | -111.53 | -128.11 |
Leverage ratios | ||||
Interest coverage | -3.19 | -2.53 | -1.71 | -3.07 |
Net debt / equity | 0.78 | 0.79 | 0.89 | 1.22 |
Net debt / op. profit | 3.41 | 3.87 | 5.58 | 6.39 |
Cost breakup (₹) | ||||
Material costs | -40.19 | -40.78 | -48.56 | -46.49 |
Employee costs | -16.59 | -16.08 | -15.28 | -15.21 |
Other costs | -24.06 | -24.38 | -22.18 | -19.15 |
EBITDA grew 48% YoY at ₹210 crore, from ₹142 crore in the same quarter last year, marking better profitability.
EBITDA rose significantly to ₹235.7 Crore, a 54% increase from ₹153 Crore in the corresponding period of the previous year.
In September 2023, the pharmaceutical behemoth revealed OneSource. The stock exchanges approved the idea earlier this year, in May.
The medication is bioequivalent and therapeutically equivalent to Schering Corp's Reference Listed Drug (RLD), THEO-DUR.
The Alathur facility is key to Strides' global operations, especially in the US and other regulated markets, specializing in the production of tablets and capsules.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
